Palvella Therapeutics, Inc. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Palvella Therapeutics, Inc. (PVLA) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$394.81 thousand for the 3-month period ending 2017-09-30, per its 10-Q filed 2017-11-13.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2017-11-13
- Palvella Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2017-09-30 was -$394.81K, a 59027.46% decline year-over-year.
- Palvella Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2017-06-30 was -$641.90K, a 704.36% decline year-over-year.
- Palvella Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2017-03-31 was $50.83K.
- Palvella Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2016-12-31 was -$176.35K.
- Palvella Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2016 was -$228.88K.
- Palvella Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2015 was -$429.48K, a 479.48% decline from fiscal 2014.
- Palvella Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2014 was $113.18K, a 389.75% increase from fiscal 2013.
- Palvella Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2013 was $23.11K.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month as first filed | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|---|
| 2017-09-30 | -$394.81K 10-Q · filed 2017-11-13 | -$1.04M derived: sum of 2 quarters · filed 2017-11-13 | -$985.88K 10-Q · filed 2017-11-13 | -$1.16M derived: sum of 4 quarters · filed 2017-11-13 | |
| 2017-06-30 | -$641.90K 10-Q · filed 2017-08-11 | -$591.07K 10-Q · filed 2017-08-11 | -$767.42K derived: sum of 3 quarters · filed 2017-08-11 | -$766.75K derived: sum of 4 quarters · filed 2017-11-13 | |
| 2017-03-31 | $50.83K 10-Q · filed 2017-05-15 | -$125.51K derived: sum of 2 quarters · filed 2017-05-15 | -$124.84K derived: sum of 3 quarters · filed 2017-11-13 | -$18.63K derived: sum of 4 quarters · filed 2017-11-13 | |
| 2016-12-31 | -$176.35K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-30 | -$175.68K derived: sum of 2 quarters · filed 2017-11-13 | -$69.47K derived: sum of 3 quarters · filed 2017-11-13 | -$228.88K 10-K · filed 2017-03-30 | |
| 2016-09-30 | $670.00 10-Q · filed 2017-11-13 | $106.88K derived: sum of 2 quarters · filed 2017-11-13 | -$52.53K 10-Q · filed 2017-11-13 | -$178.75K derived: sum of 4 quarters · filed 2017-11-13 | |
| 2016-06-30 | $106.21K 10-Q · filed 2017-08-11 | -$53.20K 10-Q · filed 2017-08-11 | -$179.42K derived: sum of 3 quarters · filed 2017-08-11 | $13.99K derived: sum of 4 quarters · filed 2017-08-11 | |
| 2016-03-31 | -$163.34K 10-Q · filed 2017-05-15 | $163.34K 10-Q · filed 2016-05-12 | -$285.63K derived: sum of 2 quarters · filed 2017-05-15 | -$92.22K derived: sum of 3 quarters · filed 2017-05-15 | $9.91K derived: sum of 4 quarters · filed 2017-05-15 |
| 2015-12-31 | -$122.30K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-30 | $71.12K derived: sum of 2 quarters · filed 2017-03-30 | $173.25K derived: sum of 3 quarters · filed 2017-03-30 | -$429.48K 10-K · filed 2017-03-30 | |
| 2015-09-30 | $193.41K 10-Q · filed 2016-11-10 | $295.55K derived: sum of 2 quarters · filed 2016-11-10 | -$307.18K 10-Q · filed 2016-11-10 | $682.13K derived: sum of 4 quarters · filed 2016-11-10 | |
| 2015-06-30 | $102.14K 10-Q · filed 2016-08-11 | -$500.60K 10-Q · filed 2016-08-11 | $488.71K derived: sum of 3 quarters · filed 2016-08-11 | $815.02K derived: sum of 4 quarters · filed 2016-08-11 | |
| 2015-03-31 | $602.73K 10-Q · filed 2016-05-12 | -$602.73K 10-Q · filed 2015-05-14 | $386.58K derived: sum of 2 quarters · filed 2016-05-12 | $712.88K derived: sum of 3 quarters · filed 2016-05-12 | $719.53K derived: sum of 4 quarters · filed 2016-05-12 |
| 2014-12-31 | -$216.15K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-23 | $110.15K derived: sum of 2 quarters · filed 2016-03-23 | $116.80K derived: sum of 3 quarters · filed 2016-03-23 | $113.18K 10-K · filed 2016-03-23 | |
| 2014-09-30 | $326.30K 10-Q · filed 2015-11-13 | $332.96K derived: sum of 2 quarters · filed 2015-11-13 | $329.33K 10-Q · filed 2015-11-13 | ||
| 2014-06-30 | $6.65K 10-Q · filed 2015-08-13 | $3.03K 10-Q · filed 2015-08-13 | |||
| 2014-03-31 | -$3.63K 10-Q · filed 2015-05-14 | ||||
| 2013-12-31 | $23.11K 10-K · filed 2015-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |